Ardea (RDEA) Initiates Potenital Gout Treatment Lesinurad Phase 3
Get Alerts RDEA Hot Sheet
Join SI Premium – FREE
Ardea Biosciences, Inc. (Nasdaq: RDEA) has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company's lead product candidate for the chronic treatment of gout. The lesinurad Phase 3 development program is expected to involve approximately 2,000 gout patients at sites around the world. The remaining Phase 3 studies in the program are expected to begin shortly.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Provides Update on the First Phase 3 YELLOWSTONE Trial of Oral Zeposia
- PayPal (PYPL) Appoint Carmine Di Sibio to its Board
- National Storage Affiliates Trust (NSA) Appoints Melissa Cameron as Chief Marketing Officer
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!